Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 1 (3)
P 2 (1)

Trial Status

Active Not Recruiting4

Clinical Trials (4)

Showing 4 of 4 trials
NCT04963153Phase 1Active Not Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04953104Phase 2Active Not Recruiting

ARID1A and/or KDM6A Mutation and CXCL13 Expression

NCT04514484Phase 1Active Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT00365157Phase 1Active Not Recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Showing all 4 trials

Research Network

Activity Timeline